Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Sep 12, 2025 (13 months ago)

Cetirizine Hydrochloride Tablets USP 10 mg

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Tablet/Capsules Imprinted with Wrong ID

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Cetirizine Hydrochloride Tablets USP 10 mg, 100 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-10.

Affected NDC 16571-0402-10

Compare with the code on your package — it is the most precise check available.

Drug: Cetirizine Category: Allergy & Cold Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cetirizine Hydrochloride
NDC 16571-0402
10 mg/1 Tablet
Oral
Rising Pharma Holdings, Inc. OTC
Recalling firm
JB Chemicals and Pharmaceuticals Ltd
NDC code
16571-402-10
Origin
India
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0032-2026 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Cetirizine recalls

See all
Class I · High risk

Cetirizine Hydrochloride Tablets USP 5 mg

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Ongoing Cross-contamination JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026
Class III · Low risk

Cetirizine hydrochloride

Labeling: Not Elsewhere classified: Product was relabeled as 90 tablet count product although it was a manufacturer in a box with 30 tablet count tablets.

Terminated Labeling / mix-up A-S Medication Solutions LLC. D-0096-2022

Other recalls by JB Chemicals and Pharmaceuticals Ltd

All 2025 recalls
Class I · High risk

Cetirizine Hydrochloride Tablets USP 5 mg

Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.

Ongoing Cross-contamination JB Chemicals and Pharmaceuticals Ltd NDC 16571-401-10 D-0732-2026
Class II · Moderate risk

Enalapril Maleate Tablets

Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test

Ongoing Impurity / degradation JB Chemicals and Pharmaceuticals Ltd NDC 64980-688-10 D-0520-2026